Peptides DB

Research-centric peptide and protocol reference hub

PE 22-28

Research-centric overview

Share
Peptide

Summary not yet generated. The Librarian will pick this up on the next daily run (12:00 UTC).

Community effect votes, structured logs, and side-effect summaries.
No effect profile data seeded yet for this peptide.

Effect scores blend an AI baseline with community votes. Open the full chart to see sliders and vote on each category.

Research log summary heatmap

Compact view of how logs describe shifts in pain, sleep, and performance (−5 to +5). Treat this as qualitative, anonymous signal only.

No community research logs yet. When structured logs are added, this panel will summarize typical shifts in pain, sleep, and performance.

Anonymous side-effect patterns

Rough heatmap of anonymous side-effect and positive-signal tags — a "most-mentioned" snapshot, not safety or efficacy advice.

No anonymous side-effect reports yet. When reports are submitted, this panel will show a simple heatmap of tags like "nausea", "flushing", "improved healing", and more.

Research footprint

Last analyzed Jun 2, 2026
4
Studies indexed
1
Human
0
Animal
4
AI analyzed
Evidence mix25% human · 0% animal · 0% cellular · 0% review
Highest phase: Preclinical onlyYears covered: 2023
Librarian pulse — latest actionsFull changelog ↓
  • Jun 2, 6:00 AMRefreshedRefreshed content for PE 22-28
  • May 28, 6:01 AMRefreshedRefreshed content for PE 22-28
  • May 26, 2:24 PMtask_runCompleted task: Refresh content for PE 22-28

Research & intelligence feed

Studies, clinical trials, community discussions, and news.

Effects of 2-Weeks of Berberine and Sprint Interval Training on Wellbeing, Anaerobic Power, and Monocyte Number and FunctionClinical TrialClinicalTrials.govPublished Jan 1, 2026Added May 27, 2026

This study measured the effects of 2 weeks of berberine and sprint interval training on wellbeing, anaerobic power, and monocyte number and function. The population and specific doses administered were not detailed in the abstract. The findings regarding the outcomes of interest were not reported in the abstract.

Phase: NAStatus: ACTIVE_NOT_RECRUITING
Chronic Hypertension and Acetyl Salicylic Acid in Pregnancy, a Multicenter Prospective Randomized Double-blind Placebo-controlled Trial.Clinical TrialClinicalTrials.govPublished Feb 15, 2021Added May 27, 2026

This study investigated the effects of acetyl salicylic acid on chronic hypertension in pregnant individuals. The trial was multicenter, prospective, randomized, double-blind, and placebo-controlled. Specific numeric outcomes and doses were not reported in the abstract.

Phase: PHASE3Status: RECRUITING
Efficacy of a Multi-component Treatment Program Integrating Cognitive - Affective - Addictive Based Intervention in Obese Patients: a Prospective Multicentric Randomized Clinical TrialClinical TrialClinicalTrials.govPublished Nov 15, 2021Added May 27, 2026

This study evaluated the efficacy of a multi-component treatment program integrating cognitive, affective, and addictive-based interventions in obese patients. The exact dose and specific outcomes measured were not detailed in the abstract. The findings suggest a prospective multicentric randomized clinical trial approach.

Phase: NAStatus: TERMINATED
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy.Clinical TrialClinicalTrials.govPublished Mar 15, 2022Added May 27, 2026

This study evaluated the efficacy and safety of Sibeprenlimab administered subcutaneously in subjects with Immunoglobulin A Nephropathy. The trial was a Phase 3, multicenter, randomized, double-blind, placebo-controlled design. Not reported in abstract.

Phase: PHASE3Status: ACTIVE_NOT_RECRUITING
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib (PRN1008) in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)Clinical TrialClinicalTrials.govPublished Dec 14, 2020Added May 27, 2026

This study evaluated the efficacy and safety of oral Rilzabrutinib (PRN1008) in adults and adolescents with persistent or chronic immune thrombocytopenia (ITP). The study design was a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial with an open-label extension. Not reported in abstract.

Phase: PHASE3Status: ACTIVE_NOT_RECRUITING
(OSKIRA-X): A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Rheumatoid ArthritisClinical TrialClinicalTrials.govPublished Jan 1, 2011Added Apr 16, 2026

This study assessed the safety and efficacy of Fostamatinib Disodium in patients with rheumatoid arthritis. The specific dose and duration were not reported in the abstract. The outcomes measured included various efficacy and safety endpoints.

Phase: PHASE3Status: TERMINATED
Phase I/II Study of LBH589 and Bevacizumab in Patients With Recurrent High Grade GliomaClinical TrialClinicalTrials.govPublished Mar 1, 2009Added Apr 16, 2026

This study evaluated the combination of LBH589 and Bevacizumab in patients with recurrent high-grade glioma. The specific outcomes measured were not detailed in the abstract. The study was conducted in a clinical setting.

Phase: PHASE1, PHASE2Status: COMPLETED
Group-based Psychoeducation for Relatives of Patients With Bipolar Disorder - a Large Scale Real-world Randomized Controlled Parallel Group TrialClinical TrialClinicalTrials.govPublished Apr 7, 2022Added Apr 16, 2026

This study evaluated the effects of group-based psychoeducation for relatives of patients with bipolar disorder. The trial involved a randomized controlled design but specific details regarding the population, dose, and outcomes are not reported in the abstract. No therapeutic claims are made.

Phase: NAStatus: COMPLETED
A Phase I/II Safety, Tolerability, Ascending Dose and Dose Frequency Study of Recombinant Human Heparan N-Sulfatase (rhHNS) Intrathecal Administration Via an Intrathecal Drug Delivery Device in Patients With Sanfilippo Syndrome Type A (MPS IIIA)Clinical TrialClinicalTrials.govPublished Jun 1, 2010Added Apr 16, 2026

This study evaluated the safety and tolerability of recombinant human heparan N-sulfatase (rhHNS) administered intrathecally in patients with Sanfilippo Syndrome Type A. The study involved ascending doses and frequency of administration. No therapeutic claims were made in the abstract.

Phase: PHASE1, PHASE2Status: COMPLETED
STUDY PROTOCOL FOR A PROSPECTIVE, MULTICENTRE, COHORT STUDY: Preeclampsia Sequential Screening Using Angiogenic Factors During First Trimester of Pregnancy (CRISP STUDY)Clinical TrialClinicalTrials.govPublished Mar 1, 2021Added Apr 16, 2026

This study protocol outlines a prospective, multicenter, cohort study aimed at screening for preeclampsia using angiogenic factors during the first trimester of pregnancy. The study's design and methodology are detailed, but specific outcomes and results are not reported in the abstract. The focus is on the potential role of angiogenic factors in early detection of preeclampsia.

Status: UNKNOWN
Semantic Scholar search for PE 22-28StudySemanticScholarAdded Dec 12, 2025

Not reported in abstract.

Decreased placental growth factor levels precede the onset of gestational diabetes mellitus: Insights into placental dysfunction and endothelial pathophysiology.StudyPubMedAdded Dec 12, 2025

Not reported in abstract.

Gestational Diabetes in Migrants: Prevalence and Metabolic Profile During Pregnancy: A Retrospective Italian Cohort Study.StudyPubMedPublished Jan 1, 2023Added Dec 12, 2025

The study explores gestational diabetes prevalence in migrant populations but lacks detailed numeric findings to support its conclusions.

Haemodynamic assessment of the superficial inferior epigastric artery to demonstrate the vascularisation of a new lower transverse abdominal flap.StudyPubMedAdded Dec 12, 2025

Not reported in abstract.

External databases

Helpful external resources for additional structural, pharmacologic, and literature context. These are third-party databases; always cross-check details with primary research.

Community notes

No comments yet. Share research notes, citations, or observations below.

Comments appear immediately.

Community research logs (detail)

No community research logs yet. Use the “Contribute data” button above to share an anonymized summary of your experience.

Anonymous side-effect reporting (detail)

This section describes how anonymous side-effect reports are aggregated into the heatmap above. Reports are anonymous and unverified, and should be read alongside primary safety data.

Use the "Report side effects" button to open a focused popup form. Please keep descriptions neutral and avoid medical language; think in terms of "nausea", "flushing", "vivid dreams", etc.

Librarian Changelog

Every time the Librarian touches this peptide — discovering, refreshing, scoring, or verifying — it logs the action here.

11h agoRefreshai-researcher70%

Refreshed content for PE 22-28

5d agoRefreshai-researcher70%

Refreshed content for PE 22-28

May 26task_runlibrarian-runner

Completed task: Refresh content for PE 22-28

May 26Refreshdiscovery50%

Refreshed content for PE 22-28

May 26SummarySemanticScholar0%

Auto-summarized study: "Semantic Scholar search for PE 22-28..."